RCEL
Get informed when a big investor buys or sells
+ FollowOvervalued by 335.6% based on the discounted cash flow analysis.
| Market cap | $107.57 Million |
|---|---|
| Enterprise Value | $101.24 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.74 |
| Beta | 1.9 |
| Outstanding Shares | 305,408,720 |
| P/E Ratio | -29.17 |
|---|---|
| PEG | 124.46 |
| Price to Sales | - |
| Price to Book Ratio | -4.16 |
| Enterprise Value to Revenue | 1.4 |
| Enterprise Value to EBIT | -4.2 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | -0.09 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 36.88% |
|---|---|
| Total Calls | 40,985,800▲ 70201.54% |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 165.81%▲ 148.50% |
|---|---|
| Total Invested | $61.57M▲ 270.04% |
| Investors Holding | 79▲ 9.00% |
No data
Oversees Medicare and Medicaid (CMS); reimbursement codes and pricing decisions determined here are critical to the commercial adoption of AVITA's products.
Controls the specific allocation of funds to agencies like BARDA, the NIH, and the VA, which are major financial drivers and customers for AVITA.
Directly oversees the FDA, which regulates the approval, labeling, and safety monitoring of all AVITA Medical products.
Oversees patent law and intellectual property rights, which are fundamental to protecting the proprietary technology behind the RECELL System.
AVITA has had significant defense-related partnerships and funding for trauma applications in combat medicine; the NDAA impacts their potential for military contracts.
The RECELL System is used in VA hospitals for trauma and burn care; committee decisions regarding VA healthcare budgets and procurement directly impact AVITA's revenue.